生物育種板塊午後拉昇 農業科技巨頭先正達擬在科創板上市
格隆匯7月6日丨生物育種板塊午後拉昇,敦煌種業午後封板,荃銀高科拉昇漲超11%,神農科技漲近10%,登海種業漲超6%,大北農、農發種業、豐樂種業、隆平高科等紛紛衝高。7月2日,上交所披露先正達的科創板首次公開發行股票招股説明書。公司在招股書中表示,2020年先正達集團在全球植保行業排名第一、種子行業排名第三、在數字農業領域處於領先地位。國信證券認為,先正達擬登陸科創板的進展超預期,其作為生物育種技術領先的種業巨頭,有望藉助上市平台優勢繼續夯實育種技術研發實力,利好我國種業創新發展,為“打好種業翻身仗”添磚加瓦。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.